New Alzheimer's disease diagnostic criteria 2024: Biological vs Clinical-biological criteria
##plugins.themes.bootstrap3.article.main##
https://orcid.org/0000-0003-2801-0537
Abstract
Regarding the development of Alzheimer’s disease biomarkers, the diagnostic criteria for the disease have been modified. Up to now, they have only been used in research, but with the advent of new biological treatments with anti-amyloid antibodies, they are beginning to be transferred to the clinic. In 2024, the working group sponsored by the Alzheimer’s Association of the US (Jack et al., 2024) proposed biological criteria for the disease based on diagnosis with biomarkers. This brings with it the problem that there are normal subjects with positive biomarkers called by them patients with asymptomatic Alzheimer’s disease. The latter was not shared by all the groups and the IWG (International Working Group) (Dubois et al., 2024) came out to mark the position that the latter are subjects “at risk” and not subjects with Alzheimer’s disease. All of this brings with it a greater gap between developed countries and those that are developing, such as Latin America. Custodio et al. (2024) discuss these difficulties and the probable proposals to implement them in the clinic in Latin America and to be able to make use of these new medications.
Downloads
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.